Stockscreener 앱 받기
6.805
5.14%
0.385
전일 마감가:
$6.42
열려 있는:
$6.51
하루 거래량:
34,911
Relative Volume:
0.14
시가총액:
$80.14M
수익:
$1.54M
순이익/손실:
$-38.70M
주가수익비율:
-1.4572
EPS:
-4.67
순현금흐름:
$-36.86M
1주 성능:
-0.59%
1개월 성능:
-20.68%
6개월 성능:
-87.91%
1년 성능:
-85.04%
1일 변동 폭
$6.465
$6.805
1주일 범위
$6.375
$7.23
52주 변동 폭
$6.375
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
CRBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
6.805 | 80.14M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
511.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.49 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.30 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.81 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.80 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
CRBP stock touches 52-week low at $6.53 amid sharp annual decline - Investing.com
Jefferies Financial Group Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Dermatomyositis Treatment Market Size Report 2034 | - openPR
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
2 Top Resilient Stocks to Buy on Trump Tariffs Dialing Into Strength - The Globe and Mail
Corbus Pharmaceuticals Advances in Oncology and Obesity - TipRanks
Corbus Pharmaceuticals: Q4 Earnings Snapshot - mySA
SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc. - Quantisnow
Corbus Pharmaceuticals Holdings Inc. (CRBP) reports earnings - Quartz
Corbus Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Corbus Pharmaceuticals Reports Q4 2024 Financial Results - TipRanks
Corbus Pharmaceuticals' cash runway expected through third-quarter 2027 -March 11, 2025 at 09:33 am EDT - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Corbus Pharmaceuticals: Q4 Earnings Snapshot -March 11, 2025 at 08:18 am EDT - Marketscreener.com
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Earnings: FDA Fast Track Status Powers $149M Cash Runway Through 2027 - StockTitan
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Raised to Sell at StockNews.com - Defense World
Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $61.38 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch
When (CRBP) Moves Investors should Listen - Stock Traders Daily
CRBP stock touches 52-week low at $7.22 amid sharp yearly decline - Investing.com India
CRBP stock touches 52-week low at $7.22 amid sharp yearly decline By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ:CRBP) Research Coverage Started at William Blair - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William Blair - MarketBeat
William Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform Recommendation - MSN
William Blair Initiates Corbus Pharmaceuticals at Outperform -February 28, 2025 at 07:57 am EST - Marketscreener.com
Corbus presents new cancer drug study at ASCO GU - MSN
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Can Corbus' Dual Focus on Oncology and Obesity Attract Investor Attention? CEO Set for Conference Circuit - StockTitan
Invalidations Everywhere… Except in Gold - The Globe and Mail
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
How To Trade (CRBP) - Stock Traders Daily
Dermatomyositis Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Treatment Market, Medication, Revenue, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
CRBP stock touches 52-week low at $7.87 amid market challenges By Investing.com - Investing.com South Africa
CRBP stock touches 52-week low at $7.87 amid market challenges - Investing.com India
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) Given “Buy” Rating at HC Wainwright - Defense World
Corbus Pharmaceuticals CEO Yuval Cohen sells shares worth $62,464 By Investing.com - Investing.com Australia
Corbus Pharmaceuticals CEO Yuval Cohen sells shares worth $62,464 - Investing.com India
Corbus Pharmaceuticals CFO Sean Moran sells $24,446 in stock - Investing.com India
Corbus Pharmaceuticals CFO Sean Moran sells $24,446 in stock By Investing.com - Investing.com Nigeria
Corbus Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
How Are Things Looking For Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) For The Short Term? - Stocks Register
Investors unsure on Corbus data for potential Padcev rival - The Pharma Letter
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.28%
0.80%
자본화:
|
볼륨(24시간):